Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in Mozambique

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202404654347323

Enrollment

888

Registered

2024-04-10

Start date

2024-05-06

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poliovirus

Interventions

nOPV2 and mOPV1

nOPV2 and bOPV vaccines

nOPV2 vaccine only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Healthy child aged 6-59 months old ? Resident in study area for the duration of the study period ? Parent/guardian consent for participation in the study ? Child included in nOPV2 study or their brothers, cousins, neighbour children

Exclusion criteria

Exclusion criteria: ? Health issue contraindication for venepuncture ? Acutely sick child or child requiring hospitalization. ? Diagnosis or suspicion of congenital immunodeficiency disorder in the subject or an immediate family member

Design outcomes

Primary

Measure	Time frame
To compare type 2 immunogenicity of two doses of nOPV2 administered alone to two doses of nOPV2 co-administered with mOPV1 and two doses of nOPV2 co-administered with bOPV.	—

Secondary

Measure	Time frame
To compare type 1 and type 3 immunogenicity of two doses of nOPV2 administered alone to two doses of nOPV2 co-administered with mOPV1 and two doses of nOPV2 co-administered with bOPV. ;To compare type 1, type 2 and 3 immunogenicity of three doses of nOPV2 administered alone to three doses of nOPV2 co-administered with mOPV1 and three doses of nOPV2 co-administered with bOPV.	—

Countries

Mozambique

Contacts

Public ContactRocio Lopes

World Health Organization

lopezro@who.int+34664664432

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026